Previous 10 | Next 10 |
SAN FRANCISCO , July 23, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2019 financial results on Tuesday, August 6, 2019 and will host a conference call and webcast that day at 4:...
Quick Take Invitae ( NVTA ) announced it has agreed to acquire Jungla for up to $65 million. Jungla has developed an Artificial Intelligence-based [AI-based] cloud genetic and genomic tests analysis platform. NVTA acquired Jungla to bring its machine learning system in-house to improve...
Genetic testing outfit Invitae ( NVTA +6.7% ) is up on average volume in apparent response to a social media post that Citron Research has a long position with a $100 (321% upside) fair value target. More news on: Invitae Corporation, Healthcare stocks news, Stocks on the move, Rea...
Invitae (NYSE: NVTA ) has agreed to acquire privately held, Andreessen Horowitz-funded Jungla , a developer of a cloud-based platform that combines clinical knowledge with advances in functional genomics, biophysics, cellular engineering, machine learning, and distributed systems to help ...
SAN FRANCISCO , July 11, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Jungla Inc. , a privately held company funded by Andreessen Horowitz (a16z) that has devel...
LOS ANGELES, June 27, 2019 (GLOBE NEWSWIRE) -- In an interview with Capital Market Laboratories (CMLviz), chief executive officer of Invitae (NYSE:NVTA) Sean George had a clear message: Invitae will never be announcing M&A in an attempt to fill a drop-in revenue. The acquisition of...
SAN FRANCISCO , June 20, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it granted time-based and development milestone-based restricted stock units ("RSUs") to new employees who joined Invitae in connection with its ...
Invitae ( NVTA +1.1% ) announces the acquisition of Singular Bio, Inc., for ~$55M, subject to certain adjustments, mostly in stock with the balance in cash. More news on: Invitae Corporation, Merger & acquisition news, Healthcare stocks news, Read more ...
SAN FRANCISCO , June 17, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Singular Bio , Inc., a privately held company developing single molecule detection technology...
Aimed at providing greater access to faster and earlier diagnosis for people who may have a genetic mutation linked to WHIM syndrome and severe congenital neutropenia, X4 Pharmaceuticals ( XFOR +2.6% ) will partner with Invitae ( NVTA -1.4% ) to offer free-of-charge genetic testin...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...